Oral News and Research

RSS

Study hopes to improve the outlook for native Americans with kidney disease

Americans have a 1 in 10 chance of suffering from kidney disease, according to statistics from the Centers for Disease Control and Prevention. For Native Americans, the risk doubles.

19 Oct 2012

Islamic Azad University develops new medicated gum for motion sickness

A new prototype for medicated chewing gum has been developed for motion sickness that may offer many advantages over conventional oral solid dosage forms. About 33 percent of people are susceptible to motion sickness in mild circumstances and 66 percent are affected in more severe conditions.

19 Oct 2012

Chelsea Clinton in Nigeria to promote program distributing zinc, oral rehydration solutions

"Chelsea Clinton is taking on the discomforting issue of diarrhea, throwing her family's philanthropic heft behind a sweeping effort in Nigeria to prevent the deaths of one million mothers and children each year from preventable causes, including 100,000 deaths from diarrhea," Reuters reports.

19 Oct 2012

Scientists report on development of new malaria drug

Scientists are reporting development of a new malaria drug that, in laboratory tests, has been twice as effective as the best current medicine against this global scourge and may fight off the disease with one dose, instead of the multiple doses that people often fail to take.

18 Oct 2012

SSRI use linked to brain hemorrhage

Use of selective serotonin reuptake inhibitors is associated with an increased risk for brain hemorrhage, particularly intracerebral bleeding, suggest meta-analysis findings.

18 Oct 2012

Gingival crevicular fluid predicts periodontal attachment loss

Analysis of gingival crevicular fluid using mass spectrometry could be used to predict sites of periodontal attachment loss in individuals undergoing maintenance therapy for periodontitis, report researchers.

18 Oct 2012

Quinic acid derivative shows promise for treating radiation exposure

A quinic acid derivative, known as KZ-41, increases 30-day survival threefold compared with placebo when given to rats 24 hours after exposure to high levels of radiation.

17 Oct 2012

Botulinum treatment benefits in BPH maybe down to placebo effect

Treatment with botulinum toxin has proved no more effective than placebo at reducing symptoms in men with lower urinary tract symptoms due to benign prostate hyperplasia, show study findings.

17 Oct 2012

Bayer’s riociguat Phase III trial data on pulmonary hypertension to be presented at ACCP meeting

Bayer HealthCare announced today that data on its investigational pulmonary hypertension compound riociguat (BAY 63-2521) will be presented in a scientific forum at the American College of Chest Physicians (ACCP) annual meeting October 20 – 25, in Atlanta, GA.

17 Oct 2012

Study determines how Trop2 protein drives growth of tumor cells in prostate and other epithelial cancers

Researchers led by Tanya Stoyanova and Dr. Owen Witte of UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have determined how a protein known as Trop2 drives the growth of tumor cells in prostate and other epithelial cancers.

17 Oct 2012

Novel drug increases survival in animal models exposed to high-dose radiation

A novel drug that mimics a naturally occurring molecule found in coffee and blueberries has been developed to treat radiation exposure. Charles R. Yates, Pharm.D., Ph.D., and colleagues Duane Miller, Ph.D., and Waleed Gaber, Ph.D., from the University of Tennessee Health Science Center and Baylor College of Medicine, show that application of this drug, starting 24 hours after radiation exposure, increases survival in animal models by three-fold compared to placebo.

17 Oct 2012

Benzocaine oral strip immediately relieves pain from burns

A dissolvable oral strip has been developed to immediately relieve pain from burns caused by ingestion of hot foods and liquids, such as coffee, pizza, and soup. This research is being presented at the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in Chicago, Ill., on Oct. 14 - 18.

17 Oct 2012

BioLineRx completes pre-clinical development of BL-8020 for HCV

BioLineRx, a biopharmaceutical development company, announced today that it has successfully completed the pre-clinical development of BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus (HCV), and plans to commence a Phase I/II safety and efficacy study for BL-8020 in Europe during the first quarter of 2013.

17 Oct 2012

NYU professor to analyze how older adults overcome barriers to accessing oral health care services

Dr. Mary E. Northridge, assistant professor of epidemiology and health promotion at the New York University College of Dentistry, has been awarded a five-year, $3.7 million grant from the National Institute of Dental and Craniofacial Research (NIDCR) and the Office of Behavioral and Social Sciences Research (OBSSR), of the National Institutes of Health (NIH), to analyze how racial and ethnic older adults living in underserved urban communities in NYC overcome barriers to accessing oral health care services.

17 Oct 2012

Best oral malodor treatment differs according to source

Oral malodor in patients with periodontitis is better treated by periodontal treatment than tongue cleaning, but both treatments are necessary to effectively remove the disease, contend the authors of a study review.

16 Oct 2012

Mother rats respond much differently to cocaine than non-mothers

Mother rats respond much differently to cocaine than female rats that have never given birth, according to new University of Michigan research that looks at both behavior and brain chemistry.

16 Oct 2012

Hepatitis C rapid and point of care tests highly accurate and reliable

Timely screening and diagnosis is critical to the success of new treatments and ultimately to the survival of hepatitis C patients. A new study led by the Research Institute of the McGill University Health Centre (RI MUHC) is the first to show that hepatitis C rapid and point of care tests with a quick turnaround time are highly accurate and reliable as conventional first-line laboratory tests.

16 Oct 2012

GAPPS announces five new projects for prevention of preterm births

Five innovative research projects aiming to prevent premature birth were announced today by the Global Alliance to Prevent Prematurity and Stillbirth (GAPPS), an initiative of Seattle Children's.

16 Oct 2012

HIV agent offers HER2-positive breast cancer hope

A drug used to treat HIV infection may be a new treatment line for patients with an aggressive type of breast cancer, US researchers believe.

15 Oct 2012

Civitas to present CVT-301 Phase 1 study results at Parkinson's Disease Therapeutics Conference

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, announced today that the Company will make its first public presentation at the Sixth Annual Parkinson's Disease Therapeutics Conference, sponsored by The Michael J. Fox Foundation for Parkinson's Research, to be held on October 24th in New York City.

15 Oct 2012